Department of Pediatrics, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
Pediatr Allergy Immunol. 2010 Jun;21(4 Pt 2):e659-66. doi: 10.1111/j.1399-3038.2010.01061.x.
The hygiene hypothesis suggests that the increased prevalence of allergic diseases has resulted from a relative lack of microbial stimuli during infancy and early childhood. Children with atopic diseases have different commensal bacterial groups in the gut compared to non-atopic children, and differences are also found between countries with high and low incidence of atopic diseases. Probiotics are defined as live microorganisms that provide benefits to the health of a host by altering the host's microflora when they are administered in adequate amounts. They are being investigated for possible roles in managing allergic diseases. To date, the evidence that probiotics can be used to treat or prevent allergic diseases of children remains controversial. We reviewed recent randomized, double-blinded, placebo-controlled clinical trials using probiotics for allergic diseases of children and evaluated their clinical efficacy, possible mechanisms, dosage, and safety for managing allergic diseases of children. The current data are insufficient to strongly recommend probiotics as a standard treatment or preventative measure for pediatric allergic disease. More studies are needed to standardize study designs, bacterial strains, dosages, and durations for different allergic diseases of children.
卫生假说表明,过敏疾病的流行增加是由于婴儿期和幼儿期相对缺乏微生物刺激。与非过敏儿童相比,患有特应性疾病的儿童的肠道中有不同的共生细菌群,而且在特应性疾病发病率高和低的国家之间也存在差异。益生菌被定义为活微生物,当以足够的量给予时,通过改变宿主的微生物群而对宿主的健康产生有益影响。它们正在被研究用于管理过敏疾病的可能作用。迄今为止,益生菌可用于治疗或预防儿童过敏疾病的证据仍然存在争议。我们回顾了最近使用益生菌治疗儿童过敏疾病的随机、双盲、安慰剂对照临床试验,并评估了它们在管理儿童过敏疾病方面的临床疗效、可能的机制、剂量和安全性。目前的数据还不足以强烈推荐益生菌作为儿童过敏疾病的标准治疗或预防措施。需要更多的研究来规范不同儿童过敏疾病的研究设计、细菌菌株、剂量和持续时间。